New Stock News | Mingyu Pharmaceutical's Hong Kong IPO prospectus invalid

According to the Wise Finance and Economics APP, the Hong Kong stock prospectus submitted by Mengyu Pharmaceuticals Co., Ltd. (referred to as Mengyu Pharmaceuticals) on November 24, 2025 has been valid for 6 months and will expire on May 24, 2026. Morgan Stanley, BofA Securities, and CITIC Securities were the joint sponsors for the submission.